A Comprehensive Guide to Hidradenitis Suppurativa, 1st Edition

A Comprehensive Guide to Hidradenitis Suppurativa, 1st Edition

Descripcion del producto

ISBN Number 9780323777247
Main Author By Vivian Y. Shi, MD, Jennifer L. Hsiao, MD, Michelle A. Lowes, MD, PhD and Iltefat H. Hamzavi, MD
Copyright Year 2022
Edition Number 1
Format Book
Trim 276 x 216 (8 1/2 x 10 7/8)
Illustrations Approx. 111 illustrations (111 in full color)
Imprint Elsevier
Page Count 368
Publication Date 20 Jan 2022
Stock Status IN STOCK

Book Description


Despite being a relatively straightforward clinical diagnosis, recognition of hidradenitis suppurativa (HS) is highly variable, and clinical management is challenging and complex.Written by the world?s leading experts in HS,A Comprehensive Guide to Hidradenitis Suppurativabrings togetherup-to-date scientific evidenceon the diagnosis,patho-mechanisms, comorbidities, and multi-faceted medical and surgical interventions for this debilitating condition?in one convenient reference.

Key Features
  • Covers every aspect of this complex skin disorder: etiology, pathophysiology, epidemiology, medical, alternative therapies, a range of surgical options, laser treatments, and comorbidities. 

  • Discusses specific patient populations such as children, women of childbearing potential, and pregnant and breastfeeding women. Because HS has higher prevalence in people of skin of color, this patient population is well-documented in the text.  

  • Offers insights into multi-disciplinary care, patient support and education, patients at risk for rapid disease progression, and clinical and translational research. 

  • Features procedural videos covering laser therapies, de-roofing procedures, excision techniques, cryoinsufflation techniques, and special wound care material selection and techniques. 

  • Includes promising future drugs and therapies that are under investigation.

  • Identifies evidence gaps that provide a springboard to the future innovations in HS care to come. 

  • Edited and authored by global experts who have helped co-author U.S., Canadian, and European guidelines on HS.  

  • Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. 


Author Information
By Vivian Y. Shi, MD, Associate Professor, Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, U.S.A.; Jennifer L. Hsiao, MD, Assistant Clinical Professor of Dermatology, Director, Hidradenitis Suppurativa Specialty Clinic, University of California, Los Angeles, California; Michelle A. Lowes, MD, PhD, Associate Professor of Clinical Investigation, The Laboratory for Investigative Dermatology, Rockefeller University, New York, New York and Iltefat H. Hamzavi, MD, Henry Ford Hospital, Clinical Associate Professor, Department of Dermatology, Wayne State University SOM; President, HS Foundation, Detroit, Michigan

Book Contents


 Foreword
1 Historic Perspectives
2 Epidemiology
3 Clinical Manifestations and Phenotypes
4 Differential Diagnosis
5 Histopathology
6 Imaging Modalities
7 Clinical Evaluation
8 Comorbidities and Systemic Associations
9 Disease Complications
10 Follicular Occlusion and Inflammation
11 Microbiome
12 Genetics and Epigenetics
13 Disease Evaluation & Outcome Measures
14 Overview and Comparison of Management Guidelines
15 Topical Therapeutics
16 Systemic Antibiotics
17 Non-Antibiotic Systemic Therapeutics for HS
18 Targeted Therapeutics: Biologics, Small Molecules
19 Pain and Itch Control
20 Wound Care
21 Quality of Life
22 Office-Based Non-Excision Procedures
23 Surgical Excisions for Hidradenitis Suppurativa
24  Office-based excision for hidradenitis suppurativa: a surgeon's decades-long experience
25 Laser and Light-Based Treatments
26 Other Procedural Treatments
27 Lifestyle Modifications
28 Complementary and Alternative Medicine (CAM)
29 Pediatrics
30 Skin of Color
31 Hidradenitis Suppurativa in Women
32 HS Action Plan
32 HS Multi-Disciplinary Approach
33 HS Support Groups
34 Pipeline Therapeutics
35 The Future